Chimerix’s (CMRX) Neutral Rating Reaffirmed at HC Wainwright
HC Wainwright restated their neutral rating on shares of Chimerix (NASDAQ:CMRX – Free Report) in a research note issued to investors on Wednesday, Marketbeat.com reports. The brokerage currently has a $8.55 price target on the biopharmaceutical company’s stock, down from their previous price target of $11.00. Separately, Wedbush reiterated an “outperform” rating and issued a […]
HC Wainwright restated their neutral rating on shares of Chimerix (NASDAQ:CMRX – Free Report) in a research note issued to investors on Wednesday, Marketbeat.com reports. The brokerage currently has a $8.55 price target on the biopharmaceutical company’s stock, down from their previous price target of $11.00. Separately, Wedbush reiterated an “outperform” rating and issued a […]
